Hormonal
Resmetirom is the first FDA-approved drug for treating noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis, demonstrating efficacy in resolving NASH without worsening fibrosis and improving fibrosis by at least one stage without worsening NASH.
Resmetirom is now the first approved medication for NASH with fibrosis. It works by targeting thyroid hormone receptors to reduce liver fat and inflammation. Patients should discuss eligibility, specifically regarding fibrosis stage, with their healthcare provider, keeping in mind the high cost and the need for ongoing monitoring.
The Food and Drug Administration (FDA) approved resmetirom (RezdiffraTM ) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis.
Why this rating
Based on FDA approval following two phase 3 RCTs meeting primary endpoints.
Source
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Maria Letizia Petroni et al. · Digestive and Liver Disease · 2024
DOI 10.1016/j.dld.2024.04.021
More from this paper
- Semaglutide, despite achieving NASH resolution, failed to improve fibrosis stage in phase 2 trials, highlighting a gap in treating advanced fibrosis compared to resmetirom.Good
- Obeticholic acid (OCA) trials for NASH were discontinued due to safety concerns and modest efficacy, despite showing some histological improvement.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →